|
Antibiotic (combination)
|
Susceptible E. cloacae (n = 2075 unique patients, 3030 isolates)
|
Multi-resistant E. cloacae (n = 373 patients, 1373 isolates)
|
Selected for WGS (n = 112 isolates)
|
|---|
|
Patients (n) tested
|
% non-susceptible / positivea
|
Patients (n) tested
|
% non- susceptible / positivea
|
% non- susceptible / positivea
|
|---|
|
ciprofloxacin
|
2075
|
1.3
|
373
|
42.9
|
28.6
|
|
colistin
|
1122
|
0
|
205
|
68.8
|
78.4b
|
|
gentamicin
|
2075
|
0.2
|
373
|
82.8
|
86.6
|
|
imipenem
|
2070
|
0.2
|
373
|
5.6
|
6.3
|
|
meropenem
|
2073
|
0.1
|
373
|
4.8
|
6.3
|
|
tobramycin
|
2075
|
0
|
373
|
89.3
|
87.5
|
|
trimethoprim/ sulfamethoxazole
|
2075
|
5.5
|
373
|
34.6
|
86.6
|
|
ESBL production
|
873
|
0
|
156
|
71.2
|
72.3
|
|
CIP or SXT
|
2075
|
0.6
|
373
|
17.7
|
5.4
|
|
CIP or SXT or MEM
|
2064
|
0
|
349
|
0.9
|
0
|
|
CIP or SXT or MEM or CST
|
1118
|
0
|
187
|
0.5
|
0
|
- CIP ciprofloxacin, CST colistin, ESBL extended-spectrum beta-lactamase, MEM meropenem, n number, SXT trimethoprim/ sulfamethoxazole, WGS whole-genome sequencing
- a% non-susceptible for antibiotics or % ESBL positive
- b111/112 isolates tested
- Number of resistant E. cloacae isolates tested: ciprofloxacin: n = 1373, colistin: n = 784, gentamicin: n = 1373, imipenem: n = 1373, meropenem: n = 1371, tobramycin: n = 1373, trimethoprim/ sulfamethoxazole: n = 1372. Number of susceptible E. cloacae isolates tested: ciprofloxacin: n = 3030, colistin: n = 1613, gentamicin: n = 3030, imipenem: n = 3024, meropenem: n = 3028, tobramycin: n = 3030, trimethoprim/ sulfamethoxazole: n = 3030
